RU2004128932A - Применение замещенных 3-фенил-5-алкокси-1,3,4-оксадиазол-2-онов для приготовления лекарственных средств с ингибирующим действием в отношении панкреатической липазы - Google Patents

Применение замещенных 3-фенил-5-алкокси-1,3,4-оксадиазол-2-онов для приготовления лекарственных средств с ингибирующим действием в отношении панкреатической липазы Download PDF

Info

Publication number
RU2004128932A
RU2004128932A RU2004128932/15A RU2004128932A RU2004128932A RU 2004128932 A RU2004128932 A RU 2004128932A RU 2004128932/15 A RU2004128932/15 A RU 2004128932/15A RU 2004128932 A RU2004128932 A RU 2004128932A RU 2004128932 A RU2004128932 A RU 2004128932A
Authority
RU
Russia
Prior art keywords
alkyl
substituted
aryl
halogen
hydrogen
Prior art date
Application number
RU2004128932/15A
Other languages
English (en)
Russian (ru)
Inventor
Карл ШЕНАФИНГЕР (DE)
Карл ШЕНАФИНГЕР
Штефан ПЕТРИ (DE)
Штефан Петри
Гюнтер МЮЛЛЕР (DE)
Гюнтер Мюллер
Армин БАУЕР (DE)
Армин БАУЕР
Хуберт Отто ХОЙЕР (DE)
Хуберт Отто ХОЙЕР
Original Assignee
АВЕНТИС ФАРМА ДОЙЧЛАНД ГмбХ (DE)
Авентис Фарма Дойчланд Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by АВЕНТИС ФАРМА ДОЙЧЛАНД ГмбХ (DE), Авентис Фарма Дойчланд Гмбх filed Critical АВЕНТИС ФАРМА ДОЙЧЛАНД ГмбХ (DE)
Publication of RU2004128932A publication Critical patent/RU2004128932A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2004128932/15A 2002-02-28 2003-02-17 Применение замещенных 3-фенил-5-алкокси-1,3,4-оксадиазол-2-онов для приготовления лекарственных средств с ингибирующим действием в отношении панкреатической липазы RU2004128932A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10208986.8 2002-02-28
DE10208986A DE10208986A1 (de) 2002-02-28 2002-02-28 Verwendung substituierter 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one zur Herstellung von Arzneimitteln mit hemmender Wirkung an der pankreatischen Lipase

Publications (1)

Publication Number Publication Date
RU2004128932A true RU2004128932A (ru) 2005-04-10

Family

ID=27740557

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2004128932/15A RU2004128932A (ru) 2002-02-28 2003-02-17 Применение замещенных 3-фенил-5-алкокси-1,3,4-оксадиазол-2-онов для приготовления лекарственных средств с ингибирующим действием в отношении панкреатической липазы

Country Status (20)

Country Link
EP (1) EP1482929A1 (fr)
JP (1) JP2005519079A (fr)
KR (1) KR20040101250A (fr)
CN (1) CN1638766A (fr)
AR (1) AR038702A1 (fr)
AU (1) AU2003210292A1 (fr)
BR (1) BR0308045A (fr)
CA (1) CA2477005A1 (fr)
CO (1) CO5611144A2 (fr)
DE (1) DE10208986A1 (fr)
HR (1) HRP20040783A2 (fr)
HU (1) HUP0500093A2 (fr)
IL (1) IL163719A0 (fr)
MA (1) MA27173A1 (fr)
MX (1) MXPA04007480A (fr)
NO (1) NO20044091L (fr)
PL (1) PL371310A1 (fr)
RU (1) RU2004128932A (fr)
TW (1) TW200400026A (fr)
WO (1) WO2003072098A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2459812C2 (ru) * 2007-12-25 2012-08-27 Киссеи Фармасьютикал Ко., Лтд. Новое производное катехина, фармацевтическая композиция, содержащая производное катехина, применение производного катехина и применение фармацевтической композиции

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI359812B (en) 2004-06-17 2012-03-11 Cytokinetics Inc Compounds, compositions and methods
MX2007004889A (es) 2004-10-25 2007-09-11 Solvay Pharm Gmbh Composiciones farmaceuticas que comprenden antagonistas del receptor cannabinoide cb1 y activadores de canales de potasio para el tratamiento de la diabetes mellitus tipo i, la obesidad y trastornos relacionados.
TW200808321A (en) 2005-12-15 2008-02-16 Cytokinetics Inc Certain chemical entities, compositions and methods
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
JP5178526B2 (ja) 2005-12-19 2013-04-10 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
WO2010074587A2 (fr) 2008-12-23 2010-07-01 Bial - Portela & Ca., S.A. 3-n-aryl-1,3,4-oxadiazolones 5-o-substituées destinées à une utilisation médicale
CN103086859B (zh) * 2011-11-08 2015-11-11 清华大学 2,4-二羟基-5,6-取代-1-卤代苯衍生物、其合成方法及其应用
EP3676243A4 (fr) * 2017-09-01 2021-05-26 Curtin University Dérivés synthétiques de oléoyl-lysophosphatidylinositol (oléolyl-lpi) et utilisations associées
CN109879839B (zh) * 2019-03-12 2023-04-25 沈阳大学 6-哌嗪甲基-7-羟基苯并呋喃类化合物及其医药用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19942354A1 (de) * 1999-09-04 2001-03-08 Aventis Pharma Gmbh Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one, ihre Herstellung und Verwendung in Arzneimitteln
HUP0302772A3 (en) * 2000-03-07 2007-03-28 Sanofi Aventis Deutschland Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one and use thereof for inhibiting hormone-sensitive lipase

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2459812C2 (ru) * 2007-12-25 2012-08-27 Киссеи Фармасьютикал Ко., Лтд. Новое производное катехина, фармацевтическая композиция, содержащая производное катехина, применение производного катехина и применение фармацевтической композиции

Also Published As

Publication number Publication date
HRP20040783A2 (en) 2005-04-30
HUP0500093A2 (hu) 2005-04-28
DE10208986A1 (de) 2003-09-11
CO5611144A2 (es) 2006-02-28
TW200400026A (en) 2004-01-01
PL371310A1 (en) 2005-06-13
KR20040101250A (ko) 2004-12-02
AU2003210292A1 (en) 2003-09-09
CN1638766A (zh) 2005-07-13
JP2005519079A (ja) 2005-06-30
NO20044091L (no) 2004-09-27
IL163719A0 (en) 2005-12-18
MA27173A1 (fr) 2005-01-03
WO2003072098A1 (fr) 2003-09-04
BR0308045A (pt) 2004-12-21
MXPA04007480A (es) 2004-11-10
CA2477005A1 (fr) 2003-09-04
AR038702A1 (es) 2005-01-26
EP1482929A1 (fr) 2004-12-08

Similar Documents

Publication Publication Date Title
RU2004128932A (ru) Применение замещенных 3-фенил-5-алкокси-1,3,4-оксадиазол-2-онов для приготовления лекарственных средств с ингибирующим действием в отношении панкреатической липазы
RU2007134380A (ru) Антибактериальные производные пиперидина
NO20091553L (no) Fenylderivater og deres anvendelse som immunmodulatorer
NO20070458L (no) Aryl-pyridinderivater som 11-Beta-HSD1 inhibitorer
WO2007125310A3 (fr) Combinaisons pharmaceutiques
RS51155B (sr) DERIVATI α -(N-SULFONAMIDO)ACETAMIDA KAO INHIBITORI β -AMILOIDA
NO20082389L (no) 2,3,4-trifenylimidazolinderivater som inhibitor av interaksjonen mellom P53- og MDM2-proteiner for anvendelse som antikreftmidler
NZ590268A (en) 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
NZ590355A (en) Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient
EP1481965A4 (fr) Derives d'amino-acides aromatiques et compositions medicamenteuses
NO20071617L (no) Indozolonderivater som 11B-HSD1-inhibitorer
TW200518740A (en) Novel peptidomimetic NS3-serine protease inhibitors of hepatitis C virus
NO20062031L (no) Derivater av N-[fenyl(alkylptpertdtn-2-yl)metyl]benzamid, fremgangsmate for fremstilling derav og anvendelse derav i terapeutiske media
NO20091409L (no) Pyridin-3-yl-derivater som immunmodulerende midler
WO2008042240A3 (fr) phosphoindoles ÉnantiomÉriquement purs utilisables en tant qu'inhibiteurs du vih
NO20091889L (no) Inhibitorer av spiroketon acetyl-CoA karboksylase
RU2002126556A (ru) Замещенные 3-фенил-5-алкокси-1,3,4-оксадиазол-2-оны и их применение для ингибирования гормоночувствительной липазы
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
AR047898A1 (es) Benzamidas sustituidas,metodos de preparacion,composiciones farmaceuticas que las contienen y usos
NO20092636L (no) Ikke-nukleosid-reverstranskriptaseinhibitorer
AR065810A1 (es) Derivados de isoindolina 4'-o-sustituidos,composiciones farmaceuticas que los comprenden y usos de los mismos en el tratamiento del cancer y en otros trastornos donde es necesario el control de la angiogenesis o la inhibicion de citoquinas, incluyendo tnf-alfa.
WO2006000371A3 (fr) Derives de pyrimidine
MX2009006598A (es) Derivados de sulfamida como transferasa de carnitina palmitoil del higado (l-cptl).
NO20052683L (no) Nye pyridopyrimidinonforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
DE602006011752D1 (de) Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20060328